ATS (ATS) Q4 2026 Earnings Call Transcript
ATS reported Q4 2026 adjusted revenues of $744 million (+3.2%); organic growth was 1.5% with a 1.7% FX benefit. Q4 adjusted earnings from operations rose 3.4% to $76.8 million; gross margin was 29.4%. Order bookings were $704 million (-18.4%) and backlog about $2 billion. Fiscal 2027 guidance calls for Q1 revenues $700–$740 million and modest full-year growth, with margin improving 50–75 bps.
How this was made
The 30-second read
Why it matters
ATS guided to modest FY2027 revenue growth incorporating a transportation revenue step-down, while targeting adjusted operating margin improvement (50–75 bps) despite additional restructuring costs ($5–$10M) and potential timing volatility in large system deliveries.
Market read
Traders can update models around FY2027 revenue step-down, restructuring costs, and margin expansion targets, while monitoring the near-term risk from weaker Q4 order bookings.
What to watch
Order bookings down 18.4% (absence of prior-year large enterprise deals) could weigh on future revenue conversion even if backlog remains ~$2B and book-to-bill is near 1.0.
Background
The article is a transcript of ATS’s Q4/FY2026 earnings call, covering results, backlog/order trends, restructuring/portfolio repositioning, and FY2027 guidance.
Ticker impact
ATS reported FY2026 and Q4 results plus FY2027 guidance, including transportation revenue step-down and margin/cost outlook.
Likely choppy/limited upside: investors may focus on the bookings decline and restructuring costs versus margin expansion targets.
The transcript provides concrete FY2027 revenue and margin expectations and quantifies restructuring and transportation revenue step-down, but also flags order-bookings weakness and timing volatility in large deliveries.
Market effects
Signals continued demand mix shift toward regulated end markets (Life Sciences/Energy) and aftermarket/service integration as a margin lever for automation/engineering peers.
No explicit regional impact described; execution and FX translation are mentioned but not quantified beyond Q4 organic/FX components.
Life Sciences and nuclear-related work mix suggests global capex/automation demand remains a key driver, with nuclear backlog growth highlighted.
Counterpoint
Margin expansion may be less reliable than management’s targets given explicit acknowledgment that the path to margin expansion “will not be linear” and large-delivery timing volatility.
Key entities
- companyATS
Reported Q4/FY2026 results and provided FY2027 revenue/margin guidance alongside transportation segment consolidation and restructuring plans.
- personDouglas Wright
CEO discussed digital twin evolution, Flex-Line platform, and margin/free-cash-flow path.
- personMichael Anne Cybulski
CFO highlighted modest growth assumptions including the transportation revenue step-down and restructuring cost expectations.
